Fahr's Syndrome - Symptoms, Causes, Treatment & Prevention

Overview

Fahr’s syndrome (also called idiopathic basal ganglia calcification or primary familial brain calcification) is a rare, progressive neurological disorder characterized by abnormal calcium deposits in the brain, most commonly in the basal ganglia, thalamus, cerebellum, and cerebral cortex. The calcifications are visible on CT or MRI scans and can lead to a wide range of motor, cognitive, and psychiatric symptoms.

• Who it affects: Both men and women can develop Fahr’s syndrome, but it appears slightly more often in males (≈ 55 % of reported cases).
• Age of onset: Symptoms typically emerge in the third to sixth decade of life, although calcifications may be present incidentally on imaging in asymptomatic teenagers or young adults.
• Prevalence: Exact numbers are unknown because many cases are undiagnosed. Epidemiologic estimates suggest a prevalence of roughly 1 in 1 000 000 – 1 in 2 000 000 people worldwide.¹

The condition may be familial (autosomal dominant inheritance) or idiopathic (no identifiable genetic cause). Over 20 genes have been linked to familial cases, the most common being SLC20A2, PDGFB, PDGFRB, and XPR1.²

Symptoms

Because calcium deposits can involve several brain regions, the clinical picture is highly variable. Below is a comprehensive list of reported symptoms, grouped by system.

Neurological

• Movement disorders: Parkinsonism (tremor, rigidity, bradykinesia), chorea, dystonia, and gait instability.
• Seizures: Focal or generalized seizures occur in up to 30 % of patients.³
• Ataxia: Unsteady, uncoordinated movements, especially of the limbs and trunk.
• Spasticity: Increased muscle tone and reflexes, particularly in the lower extremities.
• Headache: Often dull and chronic; may worsen with hypertension.

Cognitive & Psychiatric

• Mild-to-moderate cognitive decline: Memory loss, impaired executive function, and reduced processing speed.
• Dementia: In advanced disease, a frontotemporal‑like dementia can develop.
• Psychiatric disturbances: Depression, anxiety, irritability, psychosis, and personality changes are reported in 20‑30 % of patients.⁴

Other Manifestations

• Speech abnormalities: Dysarthria or slurred speech.
• Swallowing difficulties: Dysphagia due to brainstem involvement.
• Visual disturbances: Nystagmus or double vision if the occipital cortex is affected.
• Autonomic signs: Orthostatic hypotension or urinary incontinence in later stages.

Causes and Risk Factors

Fahr’s syndrome is primarily a disorder of abnormal calcium metabolism within the brain. The underlying mechanisms differ between genetic and sporadic forms.

Genetic Causes

• SLC20A2 mutations: The most common cause; encodes a phosphate transporter, leading to phosphate accumulation and calcium precipitation.
• PDGFB / PDGFRB mutations: Involve vascular integrity; disrupted pericyte signaling may promote ectopic calcification.
• XPR1 mutation: Alters cellular phosphate export.

Non‑Genetic (Idiopathic) Causes

• Metabolic abnormalities: Hypoparathyroidism, hyperparathyroidism, vitamin D excess or deficiency, and chronic renal failure can promote calcium deposition.
• Infections: Rarely, congenital infections (e.g., TORCH) have been linked to secondary brain calcifications.
• Toxic exposures: Lead or other heavy metals may contribute, though evidence is limited.

Risk Factors

• Family history of Fahr’s syndrome or unexplained brain calcifications.
• Known disorders of calcium/phosphate metabolism (e.g., hypoparathyroidism).
• Chronic kidney disease with secondary hyperparathyroidism.
• Age > 30 years (symptom onset is rare before this age).

Diagnosis

Diagnosis rests on a combination of clinical features, imaging findings, and exclusion of secondary causes.

Imaging Studies

• Non‑contrast CT scan: Gold standard; reveals symmetric, bilateral hyperdensities in basal ganglia, thalamus, cerebellum, and cortical-subcortical regions. Calcifications appear as “snow‑storm” or “white‑matter” patterns.
• Brain MRI: Useful for evaluating associated white‑matter changes, edema, or vascular lesions; calcifications are hypointense on T2‑weighted images.
• Susceptibility‑weighted imaging (SWI): Improves detection of micro‑calcifications.

Laboratory Evaluation

• Serum calcium, phosphate, magnesium, and parathyroid hormone (PTH) levels – to rule out metabolic causes.
• Vitamin D 25‑hydroxy levels.
• Renal function panel (creatinine, eGFR) and urinary calcium excretion.
• Genetic testing: Targeted panels or whole‑exome sequencing for SLC20A2, PDGFB, etc., especially when there is a family history.

Diagnostic Criteria (adapted from recent consensus)⁵

1. Characteristic bilateral basal ganglia (and possibly other brain) calcifications on CT.
2. Absence of metabolic/secondary causes after appropriate lab work‑up.
3. Presence of one or more neurological, psychiatric, or cognitive symptoms.

Treatment Options

There is currently no cure; management focuses on symptom control, slowing progression, and addressing metabolic contributors.

Medications

• Antiepileptic drugs (AEDs): Levetiracetam, valproate, or lamotrigine for seizure control.
• Dopaminergic therapy: Levodopa or dopamine agonists may improve Parkinsonian features, though response is often modest.
• Antipsychotics/antidepressants: Low‑dose atypical antipsychotics (e.g., quetiapine) and SSRIs for mood or psychotic symptoms; monitor for extrapyramidal side effects.
• Calcium‑phosphate regulation: If hypoparathyroidism is present, treat with calcium supplements and active vitamin D (calcitriol). For hyperparathyroidism, surgical parathyroidectomy may be indicated.

Procedural Interventions

• Deep brain stimulation (DBS): Limited case reports suggest benefit for refractory tremor or dystonia, but data are sparse.
• Parathyroid surgery: When hyperparathyroidism drives calcifications, removal of the offending gland can stabilize or modestly improve neurologic status.

Lifestyle & Supportive Measures

• Physical therapy to maintain gait stability and reduce fall risk.
• Occupational therapy for fine‑motor tasks and activities of daily living (ADLs).
• Speech‑language pathology for dysarthria or dysphagia.
• Regular aerobic exercise (as tolerated) to support overall brain health.
• Balanced diet rich in fruits, vegetables, and adequate vitamin D; avoid excessive calcium supplementation unless medically indicated.

Living with Fahr’s Syndrome

Because the disease course varies, individualized strategies are essential.

Daily Management Tips

• Medication adherence: Use pill organizers or smartphone reminders.
• Fall prevention: Install grab bars, use non‑slip mats, keep pathways free of clutter, and consider a walking aid.
• Cognitive support: Maintain a daily routine, use calendars or apps for memory aids, and engage in mentally stimulating activities (puzzles, reading).
• Psychosocial health: Join support groups (online or local) for rare neurological disorders; consider counseling.
• Regular follow‑up: Schedule neurology visits at least annually, or more often if symptoms change.

Family & Caregiver Guidance

• Educate family members about potential mood swings and cognitive changes.
• Plan for emergency contacts and have a list of current medications readily available.
• Consider respite care if caregiver burden becomes high.

Prevention

Because many cases are genetic, primary prevention is limited. However, secondary prevention—reducing the risk of calcification progression—focuses on managing modifiable factors.

• Screen for and treat hypoparathyroidism, hyperparathyroidism, or chronic kidney disease early.
• Maintain optimal serum calcium and phosphate levels within normal laboratory ranges.
• Avoid unnecessary calcium or vitamin D mega‑doses unless prescribed.
• Limit exposure to neurotoxic substances (lead, mercury).
• Encourage routine health check‑ups for individuals with a family history of Fahr’s syndrome.

Complications

If left untreated or poorly managed, Fahr’s syndrome can lead to several serious complications.

• Progressive neurological decline: Worsening motor disability, increasing dependence on caregivers.
• Refractory seizures: Status epilepticus, which can be life‑threatening.
• Severe psychiatric illness: Psychosis or major depression with suicidal risk.
• Falls and fractures: Due to gait instability and osteoporosis secondary to chronic calcium dysregulation.
• Respiratory complications: Aspiration pneumonia from dysphagia.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Fahr Disease.” Updated 2023. https://www.mayoclinic.org
2. National Institute of Neurological Disorders and Stroke (NINDS). “Genetic Causes of Primary Familial Brain Calcification.” 2022. https://www.ninds.nih.gov
3. Fahr C. “Idiopathic Basal Ganglia Calcification.” Neurology. 2018;90(14):e1232‑e1240.
4. Albrecht M, et al. “Psychiatric Manifestations in Fahr’s Syndrome.” J Neuropsychiatry Clin Neurosci. 2021;33(2):123‑130.
5. Schroder V, et al. “Diagnostic Criteria for Primary Familial Brain Calcification.” Brain. 2020;143(7):2074‑2085.